Synthesis of new donepezil analogs as acetylcholinesterase inhibitors

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder associated with dysfunction of the cholinergic system. The inhibition of acetylcholinesterase, the enzyme that catalyzes the hydrolysis of acetylcholine, is one of the approaches for the symptomatic treatment of Alzheimer's disease. Among the acetylcholinesterase inhibitors, donepezil is a drug approved by the FDA.